Group items tagged

This announcement solicits applications for the Improving Timeliness of Newborn Screening Diagnosis program. The purpose of the initiative is to improve the time to diagnosis and treatment for babies undergoing newborn screening (NBS) who receive a presumptive positive result. This initiative will fund one organization that will facilitate and coordinate collaborative learning and quality improvement (QI) activities by newborn screening programs using strategies that improve newborn screening timeliness. The overall goal for this initiative is to increase the number of states that meet the Secretary¿s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC or Committee) recommendations on timeliness and the number of infants receiving timely diagnosis and treatment. The SACHDNC¿s duties include providing advice and recommendations to the Secretary concerning grants and projects awarded under section 1109 of the PHS Act and making systematic evidence-based and peer-reviewed recommendations to the Secretary that include the heritable disorders that have the potential to significantly affect public health, for which all newborns should be screened. In order to achieve the best outcomes for babies, the Committee has discussed the following time periods to improve notification of results*: 1) Presumptive positive results for time-critical conditions should be communicated immediately to the child¿s healthcare provider but no later than the fifth day of life. 2) All presumptive positive results for all other conditions should be communicated to the child¿s healthcare provider as soon as possible but no later than seven (7) days of life. 3) All NBS results should be reported within seven (7) days of life. *On February 12, 2015, the DACHDNC will finalize these recommendations. The awardee is expected to use the DACHDNC¿s final recommendations. Program activites include: · Facilitate the implementation of practice-ba

The purpose of the National Public Health Practice and Resource Centers (NPHPRC) on Health for Children with Attention-Deficit/Hyperactivity Disorder (ADHD) or Tourette syndrome (TS) is to fund centers that have the capacity to develop and provide health promotion programs and health communication and education resources for both professionals and the public regarding ADHD or TS. Program strategies should include 1) Information, Consultation and Referral, 2) Health Communication Programs and Materials Development, and3) Education and Training. The NPHPRC’s mission is to provide information, education and consultation about assessment, diagnosis, treatment, and health and well-being for children with ADHD or TS. Other target audiences in the NPHPRC’s health promotion mission are health care professionals, education professionals, caregivers, and the public. Health promotion for children with ADHD or TS requires condition-specific information in addition to information and activities that address common aspects of living with ADHD or TS. The intended long-term outcomes of the program are to promote optimal health and well-being of children with ADHD or TS. Increased access to and awareness of available support services and treatments for ADHD or TS among the community, public, healthcare, and educational professionals ; increased knowledge among individuals about ADHD or TS receiving information or educational materials from the NPHPRC ; increased knowledge among individuals attending education programs on ADHD or TS; increased intention to act on information presented by adopting health behaviors, treatment or educational strategies presented among people attending education programs, receiving educational materials, or other program contents. Applications are requested according to the following target population categories: 1) Category A: National Public Health Practice and Resource Center for Children with Attention-Deficit/Hyperactivity Disorder (ADHD

The purpose of this Funding Opportunity Announcement is to support studies that will evaluate HIV drug resistance and its relationship to treatment success. Applications are sought proposing studies of genotype/phenotype correlations in diverse subtypes, the relationship between drug resistance mutations present in minority variant viral populations and treatment outcomes, and on the reasons for the discordance between genotype and treatment success or failure. Laboratory evaluations of samples with clinical correlates in patients on recommended regimens are encouraged.

Cameroon is one of the 30 countries with the highest burden of TB/HIV co-infection worldwide. Only 54% of TB cases were notified in 2016 and 5.5% were children. TB treatment coverage was 55% and treatment success 84%.Despite implementation of TB and HIV strategic plans, TB case finding, diagnosis, and management remain suboptimal. TB/HIV co-infection remains high, Isoniazid Preventive Therapy (IPT) implementation is limited, and antiretroviral therapy (ART) services are not fully integrated in TB clinics. Human resource capacity is limited, and there are continued challenges with stock management.Cameroon adheres to the Sustainable Development Goals and the WHO Strategy to END TB. This NOFO will support development of models to improve screening, case identification, prevention, diagnosis, and treatment of TB among people living with HIV (PLHIV). It will also strengthen HIV testing, ART initiation, clinical monitoring, and care for TB clients, and strengthen health systems by building monitoring and evaluation (M&E) and infection control (IC) capacity. These interventions will strengthen TB/HIV services and improve capacity for an effective TB/HIV response in Cameroon.

The National Institute on Drug Abuse (NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis. The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these deaths must be in rural communities). States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline.

The National Institute on Drug Abuse(NIDA), in partnership with the Substance Abuse and Mental Health Services Administration (SAMHSA) is soliciting cooperative agreement applications with the intention of ultimately funding up to three research sites and one data coordinating center (DCC) to participate in the 'HEALing Communities Study': Developing and Testing an Integrated Approach to Address the Opioid Crisis The HEALing Communities Study will test the immediate impact of implementing an integrated set of evidence-based interventions across healthcare, behavioral health, justice, and other community-based settings to prevent and treat opioid misuse and Opioid Use Disorders (OUD) within highly affected communities. Highly affected communities of interest could include counties or cities within states that are burdened with higher than average rates of overdose mortality and opioid-related morbidity, and other complications. Combined, all the communities participating in a single research site application must demonstrate having experienced at least 150 opioid related overdose fatalities in the past year, based on the most recent complete year of data available (15% of these must be from rural communities) . States within the top third for age-adjusted drug overdose death rates in 2016, (per the Centers for Disease Control) are of special interest. The integrated set of evidence-based prevention and treatment interventions should be designed to achieve the following goals: reduce overdose fatalities, and events; decrease the incidence of OUD; and increase the number of individuals receiving medication-assisted treatment, retained in treatment beyond 6 months, and receiving recovery support services compared to baseline .

The purpose of this Funding Opportunity Announcement (FOA) is to promote the discovery and validation of novel therapeutic targets to facilitate the development of pain therapeutics. Specifically, the focus of this FOA is on the basic science discovery of targets in the peripheral nervous system, central nervous system, immune system or other tissues in the body that can be used to develop treatments that have minimal side effects and little to no abuse/addiction liability. Research supported by this FOA must include rigorous validation studies to demonstrate the robustness of the target as a pain treatment target. This will lower the risk of adopting the target in translational projects to develop small molecules, biologics, natural substances, or devices that interact with this target for new pain treatments. Translational research to develop new medical devices are not the focus of this FOA. Basic science studies of pain and related systems in the body are responsive to this FOA and are encouraged in the context of novel pain therapeutic target discovery. This FOA is not specific for any one or group of pain conditions. Projects to identify novel targets for acute pain, chronic pain, migraine, other headache disorders, osteoarthritis, diabetic neuropathy, chemotherapy-induced neuropathy, sickle-cell pain, post stroke pain, etc. will be considered. Projects to identify novel targets for a combination of chronic overlapping pain conditions or for specific pathological conditions will be considered. Projects that seek to identify novel targets in specific populations such as women, children, older adults or other underrepresented groups will also be responsive to this FOA.

The United States Agency for International Development (USAID), through the Regional Contracting Office in Kyiv, Ukraine is seeking applications from qualified U.S. or Non-U.S. non-profit or for-profit Non-Governmental Organizations (NGOs), and other qualified non-USG organizations for funding of an activity entitled "Support TB Control Efforts in Ukraine." The purpose of Support TB Control Efforts in Ukraine Activity is to reduce the TB epidemic in Ukraine through early detection, appropriate care, and prevention for people living with TB, DR-TB and HIV/TB. The Activity will increase case detection and improve diagnostics, treatment and care for patients living with TB, DR-TB and HIV/TB co-infection. The Activity will be implemented in close cooperation with, and in support of, the National Center for Public Health of the Ministry of Health (MOH) of Ukraine. The Activity will improve the system for TB, DR-TB case diagnosis, including contact tracing, treatment initiation, treatment completion, and improved data reporting, collection and analysis.

This funding opportunity announcement (FOA) encourages research to address gaps in our knowledge of the oral health status of people living with HIV (PLWH) with an emphasis on PWLH who also have non-communicable diseases (NCDs).  It supports efforts to understand the combined effects of HIV, antiretroviral therapy (ART), and NCDs on oral health, and it encourages identification of approaches for prevention and treatment of oral diseases and assessment of treatment outcomes in PLWH with or without NCDs. These efforts could help to generate evidence for oral health treatment guidelines tailored to the needs of dental patients with HIV.

The Substance Abuse and Mental Health Services Administration (SAMHSA), Centers for Substance Abuse Treatment and Prevention are accepting applications for the fiscal year (FY) 2018 Opioid State Targeted Response (STR) Technical Assistance (TA) grant. This grant will be provided to a single entity who will serve as the central coordinating point for ensuring the requirements of this funding opportunity are met. Although there is a single grantee, applications including a consortia with other national allied professional associations are encouraged. The purpose of this program is to identify local physicians, other clinicians, and other providers, for example, advance practice nurses, physician assistants, peers and other healthcare professionals with expertise in treatment and in recovery services for opioid use disorders (OUDs). Based on a state, territory, or tribal nation's assessed need, these providers will serve as the primary providers of federally supported TA for the program's successful implementation. The goal of this TA is to ensure the provision of evidence-based prevention, treatment, and recovery support programs/services across the Opioid STR program.

The U.S. Embassy in Yaounde-Cameroon, Political and Economic Section is seeking proposals for projects that address challenges in providing community based prevention, care, and treatment services to infants, children and adolescents infected and affected by HIV/AIDS. The objective is to support increase in the number of children testing for HIV, linking those diagnosed HIV-positive to treatment, and ensuring that they stay on treatment. Additionally, recipient organizations would be engaged in encouraging and supporting retention for mothers and children enrolled in ART in order to achieve viral suppression, strengthening parent/caregiver capacity to advocate for infants, children, and adolescents with HIV, as well as supporting adolescents transitioning to adult HIV programs. We will only consider supporting projects that will be implemented in Yaounde and Douala Health Districts. Proposals can target one or more Health Districts in these cities.

The Epilepsy Foundation has announced its eighth annual epilepsy "Shark Tank" competition for the most innovative ideas in epilepsy and seizure treatment and care. Examples of novel ideas include a system to detect seizures with the capacity to provide early warning to the patient or family; a treatment that stops a seizure from progressing; a system that helps patients manage their daily treatment; a device that prevents physical injury that patients may experience when in seizure; or an entirely new product concept with the promise to dramatically improve the lives of people with epilepsy. Selected finalists will receive international recognition and compete for grants totaling $200,000 to support the development and commercialization of their new product, technology, or therapeutic concept. As many as six finalists will be selected to present at the 2019 Anti-Epileptic Drug & Device Trials, May 22-24, 2019, in Miami. Each presenter will have five minutes to present the concept, followed by five minutes of questioning. The event will feature live voting among audience members and a panel of judges (Sharks) representative of industry, advocacy, investors, and the research and medical communities. The project (or projects) deemed to be the most innovative will be announced at the conclusion of the competition. 

NIDILRR proposes to fund two Disability and Rehabilitation Research Projects of three years each to conduct research on opioid use disorder among people with disabilities. Each grant will be funded up to $500,000. Topic of interest include: 1) Systematic review of existing literature on opioid-use disorder and people with disabilities; 2) Prevalence estimates and patterns of opioid use disorder treatment for people with disabilities; 3) Factors associated with increased risk for opioid use disorder; 4) Factors associated with improved access to treatment for opioid use disorder; 5) Interventions that contribute to improved outcomes; and 6) Effects of government policies and programs on access to treatment for people with disabilities who have opioid-use disorders.

The National Institute of Mental Health invites applications to address implementation questions facing World Bank designated low- and middle-income countries (LMICs) in their efforts to scale up sustainable, evidence-based mental health interventions and thereby eliminate the mental health treatment gap for children, women, and men. The mental health treatment gap refers to the proportion of persons who need, but do not receive, care. In this funding opportunity announcement (FOA), the terms "scale up" and "going to scale" refer to intentional efforts to maximize the positive impact of mental health interventions successfully tested in experimental studies in order to benefit mental health care at the national level or at a regional level within a country, and to foster evidence-based mental health policy and program development on a lasting basis. Each awarded project is to integrate implementation research on scaling up sustainable, evidence-based mental health interventions (e.g., psychotherapeutic interventions, psychotropic medications, prevention, treatment, rehabilitation) with research capacity-building activities within LMICs in any one of the following geographical regions: East Asia and the Pacific; Europe and Central Asia; Latin America and the Caribbean; Middle East and North Africa; South Asia; Sub-Saharan Africa.  As a group, awardees of this FOA and RFA-MH-16-350 will constitute a global network for mental health implementation research in LMICs. The network will have capabilities for answering research questions about going to scale with mental health interventions, sustaining high-quality mental health care in resource-limited settings, and fostering evidence-based mental health policy and program development.

The purpose of this IHS cooperative agreement is to increase access to community-based prevention strategies to provide social detoxification, evaluation, stabilization, fostering patient readiness for and entry into treatment for alcohol use disorders and when appropriate, other substance use disorders. Applicants must have a fully operational and staffed social detoxification program that provides all three critical components of the detoxification process that primarily serves Indians. Indian Health Service (IHS) will use this funding to focus on the provision of services in the Navajo and Great Plains Areas. Congress has highlighted that the community of Gallup, New Mexico, continues to face urgent needs for substance abuse treatment, residential services, and detoxification services to address an ongoing crisis of alcohol-related deaths of Tribal members. Senate Appropriations Committee Report 114-281 expressed the Committee's expectation that IHS use funds provided in its appropriation to continue its assistance toward addressing this issue in the city of Gallup, New Mexico. Additionally, IHS is aware of the urgent need for alcohol detoxification services in the Great Plains Area after the removal of liquor licenses in White Clay, Nebraska, leading to the potential for increased mortality if services are unavailable for alcohol detoxification and subsequent treatment services.

The purpose of this RFA is to encourage studies on reproductive health, fertility and fertility preservation/treatment options in patients born with a serious chronic condition who can now expect to survive into adulthood healthy enough to consider their reproductive health and fertility options. The underlying pathophysiology of diseases such as sickle cell anemia, thalassemia, and cystic fibrosis, among others, and/or the cumulative effects of their treatment, can compromise reproductive health. This RFA encourages teams of scientists with expertise in the realm of the particular disease and in reproductive health and fertility to work together to understand the effects of the diseases and/or their treatments on parameters of reproductive health, and to identify ways to preserve, protect, or treat and reproductive deficits in these patients.

Through this Funding Opportunity Announcement (FOA), the NCI invites applications to support research in new and innovative cohort studies that identify clinical, lifestyle, genomic, and other factors that affect health outcomes (e.g., morbidity, mortality, quality of life, physical, social, and psychological outcomes) in cancer survivors. This RFA supports research that requires the creation of a new prospective cohort study of cancer survivors that addresses a gap in knowledge pertaining to the health of cancer survivors. Proposals must identify the scientific gap that the study addresses, which may include emerging treatments, less common cancer sites, and/or other understudied populations of cancer survivors with disparities. Sample size and proposed data collection must be driven by the scientific questions proposed and include information from the following five domains: 1) disease characteristics (e.g., type, stage), 2) individual survivor characteristics (e.g., comorbidities, SES, social connections, access to care measures), 3) treatment, treatment-related effects, and follow-up care (e.g. dose, adverse events, palliative care), 4) behavioral and lifestyle factors (e.g., diet, physical activity) and 5) quality of life outcomes (health related quality of life). These domains may represent exposures and/or outcomes, depending on the research questions, and should be measured at multiple timepoints, when appropriate. The UG3 Planning-Exploratory Phase focused on recruitment and data collection/utilization, and the UH3 Implementation Phase focused on completing the research agenda. Milestones to be accomplished in the UG3 phase for transition to the UH3 will be proposed by the PI, with approval by NCI, and must include a timeline for recruitment and show feasibility for data collection and analysis. Recruitment is not required to be completed in the UG3 phase, but reasonable progress should be demonstrated so that all aims will be completed in the UH3 phase.

Local governmental entities include, but are not limited to, municipal corporations, counties, cities, boroughs, incorporated towns, and townships. The purpose of this program is to allow first responders and members of other key community sectors to administer a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. Grantees will train and provide resources to first responders and members of other key community sectors at the state, tribal, and local governmental levels on carrying and administering a drug or device approved or cleared under the Federal Food, Drug, and Cosmetic Act for emergency treatment of known or suspected opioid overdose. Grantees will also establish processes, protocols, and mechanisms for referral to appropriate treatment and recovery communities. Link to Additional Information:

The purpose of this funding opportunity announcement (FOA) is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Possible topics of study include, but are not limited, to the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study designs ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research supported through this funding opportunity, outcomes will improve both in terms of the prevention and treatment of MODS in children.

The purpose of this funding opportunity announcement (FOA) is to establish a program of research to advance the understanding, prevention and treatment of pediatric multiple organ dysfunction syndrome (MODS). Given the prevalence and associated morbidity and mortality of MODS in children, the current lack of understanding underscores the need for more basic, exploratory and longitudinal research. Possible topics of study include, but are not limited, to the epidemiology, pathophysiology, monitoring, and treatment of MODS. Studies that assess specific etiologies associated with MODS including, but not limited to, sepsis, trauma, acute respiratory distress syndrome, inborn errors of metabolism, burns, cancer, transplantation and congenital heart disease are encouraged. Applications may include any appropriate study designs ranging from basic science and animal models through prospective randomized controlled trials. It is hoped that as a result of research supported through this funding opportunity, outcomes will improve both in terms of the prevention and treatment of MODS in children.